8-K: Marker Therapeutics Changes Auditors Amid Going Concern
Auditor Change
Marker Therapeutics, Inc. announced a change in its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C., effective August 6, 2025.
Summary
- Marker Therapeutics, Inc. (MRKR) changed its independent registered public accounting firm.
- Marcum LLP resigned on August 6, 2025, and CBIZ CPAs P.C. was engaged on the same date.
- CBIZ CPAs P.C. will serve as the independent registered public accounting firm for the year ending December 31, 2025, commencing with the review of the condensed consolidated financial statements for the quarter ended June 30, 2025.
- The Company's Board of Directors approved the engagement of CBIZ CPAs P.C.
- Marcum LLP's audit reports for the years ended December 31, 2024, and 2023, included an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern.
- There were no disagreements or reportable events between the Company and Marcum LLP during the periods audited or leading up to Marcum's resignation.
- Neither the Company nor anyone acting on its behalf consulted CBIZ CPAs P.C. prior to their engagement regarding accounting principles or audit opinions.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the explicit mention of 'substantial doubt about the Company's ability to continue as a going concern' in prior audit reports, which overshadows the routine nature of an auditor change.
Positives
- The transition of auditing services from Marcum LLP to CBIZ CPAs P.C. appears to be a smooth process, with no reported disagreements or reportable events between the Company and Marcum.
- The engagement of CBIZ CPAs P.C. was approved by the Company's Board of Directors, indicating proper corporate governance in the selection process.
Negatives
- Marcum LLP's audit reports for the years ended December 31, 2024, and 2023, contained an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern.
Risks
- Substantial doubt about the Company's ability to continue as a going concern, as noted in Marcum LLP's audit reports for 2023 and 2024, indicates significant financial uncertainty and potential liquidity issues.
Future Outlook
The filing does not provide specific forward-looking statements or financial guidance, focusing solely on the change in the independent registered public accounting firm.
Industry Context
Changes in independent auditors are a routine corporate governance matter. However, the disclosure of a 'going concern' explanatory paragraph in prior audit reports is a significant red flag, indicating potential financial distress that could impact the company's operations and future within the competitive biotechnology and therapeutics industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Auditor Engagement | The Company's Board of Directors approved the engagement of CBIZ CPAs P.C. as the new independent registered public accounting firm. | 2025-08-06 | Ensures continuity of independent audit services and compliance with regulatory requirements. |
Stakeholder Impact
- Shareholders: Potential negative impact due to the 'going concern' warning, which raises questions about the company's long-term viability and could lead to share price volatility.
- Creditors: May view the 'going concern' warning as an increased credit risk, potentially affecting future financing terms.
- Employees: Uncertainty regarding the company's future could impact employee morale and retention.
Next Steps
- CBIZ CPAs P.C. will review the Company's condensed consolidated financial statements for the quarter ended June 30, 2025.
- CBIZ CPAs P.C. will serve as the independent registered public accounting firm for the year ending December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 2023-12-31 | Year-end for which Marcum LLP issued an audit report containing a going concern explanatory paragraph. |
| 2024-11-01 | Effective date of CBIZ CPAs P.C.'s acquisition of Marcum LLP's attest business. |
| 2024-12-31 | Year-end for which Marcum LLP issued an audit report containing a going concern explanatory paragraph. |
| 2025-06-30 | End of the quarter for which CBIZ CPAs P.C. will begin their review of the Company's condensed consolidated financial statements. |
| 2025-08-06 | Date Marcum LLP resigned as the Company's independent registered public accounting firm and CBIZ CPAs P.C. was engaged. |
| 2025-08-07 | Date of earliest event reported in the Form 8-K. |
| 2025-08-12 | Date the Form 8-K was signed and the date of Marcum LLP's letter to the SEC (Exhibit 16.1). |
| 2025-12-31 | Year-end for which CBIZ CPAs P.C. will serve as the independent registered public accounting firm. |
Recommendation
sellThe explicit disclosure of 'substantial doubt about the Company's ability to continue as a going concern' in prior audit reports is a critical red flag. While the auditor change itself is a procedural matter, the underlying financial health indicated by the going concern warning suggests significant operational and financial risks. Investors should consider selling to mitigate potential losses given the severe uncertainty regarding the company's future viability.
Keywords
Marker Therapeutics, MRKR, SEC filing, 8-K, auditor change, accounting firm, going concern, financial reporting, corporate governance, biotechnology, therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.